咳嗽性過敏症症候群の世界市場レポート 2025年

咳嗽性過敏症症候群市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.4％で146億5,000万米ドルに成長します。予測期間の成長は、世界の医療アクセス、患者擁護と支援、生活の質の向上に起因しています。予測期間の主な動向には、診断・スクリーニングツールの改善、個別化治療アプローチ、新薬などがあります。

慢性呼吸器疾患の有病率の増加は、咳嗽性過敏症症候群市場の拡大を促進すると予測されます。慢性呼吸器疾患（CRDs）には、肺や気道に影響を及ぼすさまざまな長期疾患が含まれ、呼吸の課題が継続し、肺機能が徐々に低下します。咳嗽性過敏症症候群の治療は、症状の緩和、呼吸機能の改善、喘息などのCRD患者の生活の質の向上に役立ちます。例えば、2023年6月、オーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、オーストラリア人口の約30％、750万人が慢性呼吸器疾患に罹患していると報告しました。さらに、2024年5月、米国の国立保健統計センター（NCHS）は、成人の喘息有病率が2021年の8.4％から2022年には8.7％に増加し、同じ期間に成人の喘息エピソード発生率が3.3％から3.7％に上昇したことを示しました。このように、慢性呼吸器疾患の増加が咳嗽性過敏症症候群市場の成長を促進しています。

タバコを吸う人の増加は、近い将来、咳嗽性過敏症症候群市場の拡大を促進する重要な要因になると予測されています。紙巻きタバコの喫煙者は、紙巻きタバコの葉を燃やして発生する煙を吸引することで、定期的に紙巻きタバコを喫煙する個人です。タバコは、気道に刺激を与え、炎症を誘発し、肺組織に損傷を与えることによって、咳嗽性過敏症症候群を誘発します。例えば、2022年7月現在、カナダ統計局は2021年6月と比較してタバコの生産量が5.8％増加したと報告しています。さらに、タバコの総販売本数は1.3％増加し、2022年6月には14億本に達しました。さらに、2023年5月、米国疾病予防管理センターは、推定2830万人の米国成人がたばこ喫煙者であり、約308万人の米国中高生が少なくとも1つのたばこ製品を使用していることを明らかにしました。毎日、約1600人の18歳未満の米国青少年が最初のタバコを試しています。したがって、たばこ喫煙者の人口増加は、咳嗽性過敏症症候群市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界咳嗽性過敏症症候群 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の咳嗽性過敏症症候群市場：成長率分析
• 世界の咳嗽性過敏症症候群市場の実績：規模と成長, 2019-2024
• 世界の咳嗽性過敏症症候群市場の予測：規模と成長, 2024-2029, 2034F
• 世界咳嗽性過敏症症候群総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の咳嗽性過敏症症候群市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイドを吸入する
• 鎮咳剤
• 短時間作用型ベータ2刺激薬
• 抗コリン薬
• プロトンポンプ阻害剤
• 抗ヒスタミン薬
• その他の薬物
• 世界の咳嗽性過敏症症候群市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 吸入
• その他の投与経路
• 世界の咳嗽性過敏症症候群市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の咳嗽性過敏症症候群市場吸入ステロイド薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブデソニド
• フルチカゾン
• ベクロメタゾン
• 世界の咳嗽性過敏症症候群市場鎮咳薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デキストロメトルファン
• コデイン
• ベンゾナテート
• 世界の咳嗽性過敏症症候群市場、短時間作用型ベータ2刺激薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルブテロール
• レバルブテロール
• 世界の咳嗽性過敏症症候群市場抗コリン薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• イプラトロピウム臭化物
• チオトロピウム
• 世界の咳嗽性過敏症症候群市場プロトンポンプ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オメプラゾール
• エソメプラゾール
• ランソプラゾール
• 世界の咳嗽性過敏症症候群市場抗ヒスタミン薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• セチリジン
• ロラタジン
• ジフェンヒドラミン
• 世界の咳嗽性過敏症症候群市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 粘液溶解薬
• 併用療法薬

第7章 地域別・国別分析

• 世界の咳嗽性過敏症症候群市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の咳嗽性過敏症症候群市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 咳嗽性過敏症症候群市場：競合情勢
• 咳嗽性過敏症症候群市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck and Co Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca Plc.
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim GmbH
• Wyeth Pharmaceuticals Inc.
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Lupin Limited
• Cadila Pharmaceuticals
• Almirall S.A.
• Akorn Operating Company LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 咳嗽性過敏症症候群市場2029：新たな機会を提供する国
• 咳嗽性過敏症症候群市場2029：新たな機会を提供するセグメント
• 咳嗽性過敏症症候群市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cough hypersensitivity syndrome (CHS) is a medical condition characterized by an exaggerated and abnormal response of the cough reflex to various stimuli, often leading to persistent and chronic coughing. It is commonly associated with conditions such as asthma, gastroesophageal reflux disease (GERD), and upper airway disorders.

The main drug types used for treating cough hypersensitivity syndrome include inhaled corticosteroids, antitussive agents, short-acting beta-2 agonists, anticholinergics, proton pump inhibitors, antihistamines, and others. Inhaled corticosteroids (ICS) refer to a class of medications used in the treatment of various respiratory conditions. These drugs can be administered orally, through inhalation, or by other means. They are utilized by various end-users, including hospitals, specialty clinics, homecare services, and others.

The cough hypersensitivity syndrome market research report is one of a series of new reports from The Business Research Company that provides cough hypersensitivity syndrome market statistics, including cough hypersensitivity syndrome industry global market size, regional shares, competitors with a cough hypersensitivity syndrome market share, detailed cough hypersensitivity syndrome market segments, market trends and opportunities and any further data you may need to thrive in the cough hypersensitivity syndrome industry. This cough hypersensitivity syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cough hypersensitivity syndrome market size has grown strongly in recent years. It will grow from $10.36 billion in 2024 to $11.03 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased awareness, telemedicine and remote monitoring, public health initiatives, research funding.

The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $14.65 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to global health access, patient advocacy and support, quality of life improvements. Major trends in the forecast period include improved diagnosis and screening tools, personalized treatment approaches, new medications.

The growing prevalence of chronic respiratory diseases is anticipated to drive the expansion of the cough hypersensitivity syndrome market. Chronic respiratory diseases (CRDs) encompass a range of long-term conditions affecting the lungs and airways, which lead to ongoing breathing challenges and gradual declines in lung function. Treatment for cough hypersensitivity syndrome helps alleviate symptoms, improve respiratory function, and enhance the quality of life for individuals with CRDs, such as asthma. For example, in June 2023, the Australian Institute of Health and Welfare reported that nearly 30% of the Australian population, or 7.5 million people, are affected by chronic respiratory diseases. Additionally, in May 2024, the National Center for Health Statistics (NCHS) in the United States indicated that adult asthma prevalence increased from 8.4% in 2021 to 8.7% in 2022, with asthma episode incidence for adults rising from 3.3% to 3.7% over the same period. Thus, the increasing occurrence of chronic respiratory diseases is fueling growth in the cough hypersensitivity syndrome market.

The increasing population of cigarette smokers is anticipated to be a significant factor propelling the expansion of the cough hypersensitivity syndrome market in the foreseeable future. Cigarette smokers are individuals who regularly engage in tobacco use by smoking cigarettes, involving the inhalation of smoke generated from burning tobacco leaves encased in a paper-wrapped cylinder. Cigarette smoking induces cough hypersensitivity syndrome by provoking irritation in the airways, inciting inflammation, and causing damage to lung tissues. For instance, as of July 2022, Statistics Canada reported a 5.8% increase in cigarette production compared to June 2021. Additionally, the total number of cigarettes sold rose by 1.3%, reaching 1.4 billion in June 2022. Furthermore, in May 2023, the Centers for Disease Control and Prevention revealed that an estimated 28.3 million U.S. adults are cigarette smokers, with about 3.08 million U.S. middle and high school students using at least one tobacco product. Each day, approximately 1,600 U.S. youth under the age of 18 try their first cigarette. Therefore, the growing population of cigarette smokers is expected to drive the growth of the cough hypersensitivity syndrome market.

Leading companies in the cough hypersensitivity syndrome market are prioritizing the development of advanced asthma treatments, such as rescue inhalers, to enhance patient outcomes and improve quality of life. Asthma rescue inhalers are compact devices designed to deliver quick-relief medication, helping to open airways rapidly. They provide relief from sudden coughing fits by temporarily easing airway sensitivity and reducing cough-related obstructions. For example, in April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, entered a partnership with Launch Therapeutics, a clinical development firm in the United States. This collaboration focuses on accelerating the clinical program for Teva's ICS-SABA inhaler, TEV-'248, which combines fluticasone propionate and albuterol sulfate, and is intended for both adult and pediatric asthma patients. This effort also aims to decrease dependency on generic treatments.

In June 2023, GlaxoSmithKline PLC, a prominent UK-based pharmaceutical and biotechnology company specializing in the production of drugs for cough hypersensitivity syndrome, completed the acquisition of Bellus Health Inc. for $2.0 billion. Through this strategic move, GSK aims to bolster its array of respiratory medications, as well as enhance its capabilities in research and development, production, and commercialization. Bellus Health Inc. is a biotechnology company based in Canada, known for its development of drugs tailored for cough hypersensitivity syndrome.

Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.

North America was the largest region in the cough hypersensitivity syndrome market in 2024. The regions covered in cough hypersensitivity syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cough hypersensitivity syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cough hypersensitivity syndrome market consists of sales of cough suppressants, steam inhalers and humidifiers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cough Hypersensitivity Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cough hypersensitivity syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cough hypersensitivity syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cough hypersensitivity syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Inhales Corticosteroids; Antitussive Agents; Short-acting Beta-2 Agonists; Anticholinergics; Proton Pump Inhibitors; Antihistamines; Other Drugs
• 2) By Route of Administration: Oral; Inhalation; Other Route Of Administration
• 3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Inhaled Corticosteroids: Budesonide; Fluticasone; Beclomethasone
• 2) By Antitussive Agents: Dextromethorphan; Codeine; Benzonatate
• 3) By Short-acting Beta-2 Agonists: Albuterol; Levalbuterol
• 4) By Anticholinergics: Ipratropium Bromide; Tiotropium
• 5) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole
• 6) By Antihistamines: Cetirizine; Loratadine; Diphenhydramine
• 7) By Other Drugs: Mucolytics; Combination Therapy Drugs
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; F. Hoffmann-La Roche AG; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cough Hypersensitivity Syndrome Market Characteristics

3. Cough Hypersensitivity Syndrome Market Trends And Strategies

4. Cough Hypersensitivity Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cough Hypersensitivity Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cough Hypersensitivity Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cough Hypersensitivity Syndrome Market Growth Rate Analysis
• 5.4. Global Cough Hypersensitivity Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cough Hypersensitivity Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cough Hypersensitivity Syndrome Total Addressable Market (TAM)

6. Cough Hypersensitivity Syndrome Market Segmentation

• 6.1. Global Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhales Corticosteroids
• Antitussive Agents
• Short-acting Beta-2 Agonists
• Anticholinergics
• Proton Pump Inhibitors
• Antihistamines
• Other Drug
• 6.2. Global Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Inhalation
• Other Route Of Administration
• 6.3. Global Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.4. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Budesonide
• Fluticasone
• Beclomethasone
• 6.5. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Antitussive Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dextromethorphan
• Codeine
• Benzonatate
• 6.6. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Albuterol
• Levalbuterol
• 6.7. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ipratropium Bromide
• Tiotropium
• 6.8. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• 6.9. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cetirizine
• Loratadine
• Diphenhydramine
• 6.10. Global Cough Hypersensitivity Syndrome Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mucolytics
• Combination Therapy Drugs

7. Cough Hypersensitivity Syndrome Market Regional And Country Analysis

• 7.1. Global Cough Hypersensitivity Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cough Hypersensitivity Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cough Hypersensitivity Syndrome Market

• 8.1. Asia-Pacific Cough Hypersensitivity Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cough Hypersensitivity Syndrome Market

• 9.1. China Cough Hypersensitivity Syndrome Market Overview
• 9.2. China Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cough Hypersensitivity Syndrome Market

• 10.1. India Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cough Hypersensitivity Syndrome Market

• 11.1. Japan Cough Hypersensitivity Syndrome Market Overview
• 11.2. Japan Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cough Hypersensitivity Syndrome Market

• 12.1. Australia Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cough Hypersensitivity Syndrome Market

• 13.1. Indonesia Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cough Hypersensitivity Syndrome Market

• 14.1. South Korea Cough Hypersensitivity Syndrome Market Overview
• 14.2. South Korea Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cough Hypersensitivity Syndrome Market

• 15.1. Western Europe Cough Hypersensitivity Syndrome Market Overview
• 15.2. Western Europe Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cough Hypersensitivity Syndrome Market

• 16.1. UK Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cough Hypersensitivity Syndrome Market

• 17.1. Germany Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cough Hypersensitivity Syndrome Market

• 18.1. France Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cough Hypersensitivity Syndrome Market

• 19.1. Italy Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cough Hypersensitivity Syndrome Market

• 20.1. Spain Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cough Hypersensitivity Syndrome Market

• 21.1. Eastern Europe Cough Hypersensitivity Syndrome Market Overview
• 21.2. Eastern Europe Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cough Hypersensitivity Syndrome Market

• 22.1. Russia Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cough Hypersensitivity Syndrome Market

• 23.1. North America Cough Hypersensitivity Syndrome Market Overview
• 23.2. North America Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cough Hypersensitivity Syndrome Market

• 24.1. USA Cough Hypersensitivity Syndrome Market Overview
• 24.2. USA Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cough Hypersensitivity Syndrome Market

• 25.1. Canada Cough Hypersensitivity Syndrome Market Overview
• 25.2. Canada Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cough Hypersensitivity Syndrome Market

• 26.1. South America Cough Hypersensitivity Syndrome Market Overview
• 26.2. South America Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cough Hypersensitivity Syndrome Market

• 27.1. Brazil Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cough Hypersensitivity Syndrome Market

• 28.1. Middle East Cough Hypersensitivity Syndrome Market Overview
• 28.2. Middle East Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cough Hypersensitivity Syndrome Market

• 29.1. Africa Cough Hypersensitivity Syndrome Market Overview
• 29.2. Africa Cough Hypersensitivity Syndrome Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cough Hypersensitivity Syndrome Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cough Hypersensitivity Syndrome Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cough Hypersensitivity Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Cough Hypersensitivity Syndrome Market Competitive Landscape
• 30.2. Cough Hypersensitivity Syndrome Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Cough Hypersensitivity Syndrome Market Other Major And Innovative Companies

• 31.1. Merck and Co Inc.
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca Plc.
• 31.5. GlaxoSmithKline Plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Boehringer Ingelheim GmbH
• 31.8. Wyeth Pharmaceuticals Inc.
• 31.9. AstraZeneca Pharmaceuticals LP
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. Lupin Limited
• 31.13. Cadila Pharmaceuticals
• 31.14. Almirall S.A.
• 31.15. Akorn Operating Company LLC

32. Global Cough Hypersensitivity Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cough Hypersensitivity Syndrome Market

34. Recent Developments In The Cough Hypersensitivity Syndrome Market

35. Cough Hypersensitivity Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Cough Hypersensitivity Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cough Hypersensitivity Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cough Hypersensitivity Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer